Table 1. Patient demographics of the 58 patients evaluated in this concentration–effect analysis (providing 280 plasma samples).

	Patients		Samples
Characteristic	CML	GIST	CML	GIST
Pathology diagnosis (no.)
GIST		38		227
CML	20		53
Gender (no.)
Men	9	24	23	138
Women	11	14	30	89
Age (years)
Median			48	57
Range			27–71	20–79
Imatinib daily dose (mg)
Median			400	600
Range			150–800	200–800
AGP plasma levels (g per l)
Median			0.7	0.9
Range			0.4–3.0	0.4–3.2
KIT genotype (no.)
Exon 11 mutation		13		78
Exon 9 mutation or wt KIT		7		50
Not available		18		99
Side effects incidence (no.)
0			19	52
1			15	62
2			10	68
3 or more			9	45
Haematological Response score (no.)
No response (NHR)			7
Partial response (PHR)			20
Complete response (CHR)			26
RECIST response score (no.)
Progressive disease (PD)				58
Stable disease (SD)				72
Partial response (PR)				87
Complete response (CR)				10
Dichotomous response (no.)
Progressive or stable disease (SD+PD)				130
Overall responses (OR=PR+CR)				97